ScoreWhy is Mabwell (Shanghai) Bioscience Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 171.88% and Operating profit at -7.46% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has reported losses. Due to this company has reported negative ROE
3
Poor long term growth as Net Sales has grown by an annual rate of 171.88% and Operating profit at -7.46% over the last 5 years
4
The company has declared Negative results for the last 4 consecutive quarters
- ROCE(HY) Lowest at -70.75%
- DEBT-EQUITY RATIO (HY) Highest at 150.39 %
- INTEREST(Q) Highest at CNY 22.37 MM
5
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 68.98%, its profits have fallen by -6.2%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Mabwell (Shanghai) Bioscience Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Mabwell (Shanghai) Bioscience Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Mabwell (Shanghai) Bioscience Co., Ltd.
102.13%
0.00
73.82%
China Shanghai Composite
25.09%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
171.88%
EBIT Growth (5y)
-7.46%
EBIT to Interest (avg)
-92.39
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.87
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
23.55
EV to EBIT
-18.01
EV to EBITDA
-21.57
EV to Capital Employed
11.11
EV to Sales
115.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-61.68%
ROE (Latest)
-140.93%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY -390.14 MM
OPERATING PROFIT MARGIN(Q)
Highest at -1.85 %
RAW MATERIAL COST(Y)
Fallen by -241.42% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 4.9 times
NET SALES(Q)
Highest at CNY 464.67 MM
OPERATING PROFIT(Q)
Highest at CNY -8.6 MM
PRE-TAX PROFIT(Q)
Highest at CNY -27.8 MM
NET PROFIT(Q)
Highest at CNY -46.6 MM
EPS(Q)
Highest at CNY -0.12
-15What is not working for the Company
ROCE(HY)
Lowest at -70.75%
DEBT-EQUITY RATIO
(HY)
Highest at 150.39 %
INTEREST(Q)
Highest at CNY 22.37 MM
Here's what is working for Mabwell (Shanghai) Bioscience Co., Ltd.
Net Sales
At CNY 464.67 MM has Grown at 902.43%
over average net sales of the previous four periods of CNY 46.35 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (CNY MM)
Operating Profit Margin
Highest at -1.85 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Cash Flow
Highest at CNY -390.14 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
Highest at CNY 464.67 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY -8.6 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Pre-Tax Profit
Highest at CNY -27.8 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY -27.8 MM has Grown at 90.32%
over average net sales of the previous four periods of CNY -287.21 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY -46.6 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Net Profit
At CNY -46.6 MM has Grown at 83.8%
over average net sales of the previous four periods of CNY -287.65 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY -0.12
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debtors Turnover Ratio
Highest at 4.9 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -241.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Mabwell (Shanghai) Bioscience Co., Ltd.
Debt-Equity Ratio
Highest at 150.39 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
Highest at CNY 22.37 MM
in the last five periods and Increased by 8.9% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
